Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis of observational studies

doi:10.1016/j.semarthrit.2014.03.004

Seminars in Arthritis and Rheumatism

Volume 44, Issue 1, August 2014, Pages 63-67

https://doi.org/10.1016/j.semarthrit.2014.03.004 Get rights and content

Abstract

Objectives

To investigate the risk of coronary artery disease in patients with idiopathic inflammatory myopathies (IIM).

Methods

We conducted a systematic review and meta-analysis of observational studies that reported odds ratios, relative risks, hazard ratios, or standardized incidence ratios comparing the risk of coronary artery disease in patients with IIM versus non-IIM participants. We searched published studies indexed in MEDLINE, EMBASE, and the Cochrane database from inception to December 2013 using the terms “coronary artery disease” OR “coronary heart disease” OR “myocardial infarction” OR “atherosclerosis” combined with the terms “dermatomyositis” OR “polymyositis” OR “Idiopathic inflammatory myopathy.” Pooled risk ratio and 95% confidence interval were calculated using a random-effect, generic inverse variance method.

Result

Overall, four studies were identified and included for data analysis. The pooled risk ratio of CAD in patients with IIM was 2.24 (95% CI: 1.02–4.92). The statistical heterogeneity of this meta-analysis was high with an I² of 97%.

Conclusion

Our study demonstrated a statistically significant increased risk of CAD among patients with IIM.

Introduction

Idiopathic inflammatory myopathies (IIM) are a group of chronic systemic inflammatory disorders that primarily affect the skeletal muscle. The most common subtypes are dermatomyositis (DM) and polymyositis (PM) [1], [2], [3]. The association between chronic inflammation and accelerated atherosclerosis is well-established [4], [5], and several chronic inflammatory disorders, including rheumatoid arthritis (RA), psoriasis, and systemic lupus erythematosus, have been shown to be associated with an increased risk of coronary artery disease (CAD) in large epidemiological studies [6], [7], [8]. Nevertheless, the data on CAD in patients with IIM is unclear, and the results from large epidemiological studies are conflicting. Thus, to further investigate this association, we conducted a systematic review and meta-analysis of case–control and cohort studies that compared the risk of coronary artery disease in patients with IIM versus non-IIM.

Section snippets

Search strategy

Two investigators (P.U. and P.S.) independently searched published studies indexed in MEDLINE, EMBASE, and the Cochrane database from inception to December 2013 using the terms “coronary artery disease” OR “coronary heart disease” OR “myocardial infarction” OR “atherosclerosis” combined with the terms “dermatomyositis” OR “polymyositis” OR “Idiopathic inflammatory myopathy.” A manual search of references of selected retrieved studies was also performed. Abstract and unpublished studies were not

Result

Our search strategy yielded 392 potentially relevant articles. A total of 379 articles was excluded as they were not observational studies or were not done in patients with IIM. Therefore, 13 articles underwent full-length article review. Of them, five were excluded as they did not report the outcome of interest (coronary artery disease) while four of them were excluded as they were review articles. Overall, four studies (three cohort studies and one case–control study) with 13,201 patients

Discussion

This is the first systematic review and meta-analysis of published observational studies assessing the risk of CAD in patients with DM or PM. Our study demonstrates a significant association between IIM and CAD with an overall 2.24-fold increased risk compared with non-IIM participants. All cohort studies reported a positive association between IIM and CAD, and in fact, the relative risks were fairly consistent among the cohort studies [11], [12], [13] while the only case–control study did not

Conclusion

The results of our meta-analysis demonstrate a statistically significant increased CAD risk among patients with IIM. A physician should be aware of this association, and traditional cardiovascular risk factors modification should be part of standard of care in this group of patients.

Reference (28)

R. Voisard et al.
Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro
Int J Cardiol
(1994)
Ungprasert P, Leeaphorn N, Hosiriluck N, Chaiwatcharayut W, Ammannagari N, Raddatz DA. Clinical features of...
A. Bohan et al.
Polymyositis and dermatomyositis-I
New Engl J Med
(1975)
A. Bohan et al.
Polymyositis and dermatomyositis (second of tow parts)
New Engl J Med
(1975)
J. Frostegard
Atherosclerosis in patients with autoimmune disorders
Arterioscler Thromb Vasc Biol
(2005)
P. Libby
Inflammation in atherosclerosis
Nature
(2002)
H. Maradit-Kremers et al.
Cardiovascular death in rheumatoid arthritis: a population-based study
Arthritis Rheum
(2005)
R. Bessant et al.
Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus
Rheumatology (Oxford)
(2004)
E. Vizzardi et al.
Psoriasis and cardiovascular diseases
Acta Cardiol
(2010)
A. Stang
Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Eur J Epidemiol
(2010)

J.P. Higgins et al.

Measuring inconsistency in metaanalyses

Br Med J

(2003)

A. Tisseverasinghe et al.

Arterial events in persons with dermatomyositis and polymyositis

J Rheumatol

(2009)

B. Zoller et al.

Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden

PLoS One

(2012)

Y.T. Lai et al.

Dermatomyositis is associated with an increased risk of cardiovascular and cerebrovascular events: a Taiwanese population-based longitudinal follow up study

Br J Dermatol

(2013)

Cited by (61)

Clinical characterisation of patients with inflammatory myopathy in 2 tertiary care hospitals in Colombia: A descriptive survey
2022, Revista Colombiana de Reumatologia
Existe poca información sobre las miopatías inflamatorias en Colombia. El objetivo fue identificar las características demográficas y clínicas de estos pacientes en dos instituciones de alta complejidad entre los años 2010 y 2015.
Se realizó un estudio descriptivo y retrospectivo. Mediante revisión de registros médicos, se obtuvo información sobre variables demográficas y clínicas. Las variables cualitativas se expresaron mediante frecuencias absolutas y relativas, y las cuantitativas con media y desviación estándar (DE) o mediana con rangos intercuartílicos (RIQ), dependiendo de la distribución de los datos. Se utilizó el paquete estadístico IBM SPSS® v.22.
Se incluyeron 105 pacientes con edad promedio de 50,4 años (DE: 15,1); 76 mujeres (72,4%). En total, 50 sujetos (48,5%) tuvieron diagnóstico definitivo. La miopatía inflamatoria más común fue dermatomiositis (n = 66; 62,9%). La piel fue el órgano más comúnmente afectado (n = 66; 62,9%). La debilidad muscular estuvo presente en 60 individuos (57,1%). El signo de alarma más frecuente fue el trastorno de la deglución (n = 28; 26,7%). La creatinfosfoquinasa tuvo mayor elevación en polimiositis con una mediana de 1.800 UI/l (RIQ: 365-6.157). Los medicamentos más utilizados fueron los glucocorticoides (n = 83; 79%). Hubo refractariedad al tratamiento inmunosupresor, principalmente en síndrome antisintetasa (n = 5; 35,7%). Cinco pacientes (4,8%) murieron por infecciones (neumonía y bacteriemia).
En esta cohorte, la entidad más común fue la dermatomiositis y el órgano más afectado fue la piel. Hubo presentación relevante de signos de alarma, refractariedad al tratamiento inmunosupresor y valores de enzimas musculares menores comparados con otras cohortes. La mortalidad fue principalmente por complicaciones infecciosas.
There is little information on inflammatory myopathies in Colombia. The objective was to identify the demographic and clinical characteristics of these patients in two tertiary care hospitals between 2010 and 2015.
A descriptive, retrospective survey was carried out, by reviewing medical records and obtaining information on demographic and clinical variables. The qualitative variables were expressed using absolute and relative frequencies, and the quantitative with mean and standard deviation (SD), or median with interquartile ranges (IQR), depending on data distribution. The IBM SPSS 22 statistical package was used.
A total of 105 patients with a mean age of 50.4 years (SD: 15.1) were included, with 76 (72.4%) women. In total, 50 subjects (48.5%) had a definitive diagnosis. The most common inflammatory myopathy was dermatomyositis (n=66; 62.9%). The skin was the most commonly affected organ (n=66; 62.9%). Muscle weakness was present in 60 individuals (57.1%). The most frequent alarm sign was swallowing disorder (n=28; 26.7%). Creatine phosphokinase was higher in polymyositis, with a median of 1800 IU/L (IQR: 365-6157). The most widely used drugs were glucocorticoids (n=83; 79%). Some patients were refractory to immunosuppressive treatment, mainly in antisynthetase syndrome (n=5; 35.7%). Five patients (4.8%) died of infections (pneumonia and bacteraemia).
In this cohort, the most common entity was dermatomyositis, and the most affected organ was the skin. There was a significant presentation of warning signs, refractoriness to immunosuppressive treatment, and lower muscle enzyme values compared to other cohorts. Mortality was mainly due to infectious complications.
Cardiovascular Risk Factors and Atherosclerotic Cardiovascular Events Among Incident Cases of Systemic Sclerosis: Results From a Population-Based Cohort (1980-2016)
2020, Mayo Clinic Proceedings
Citation Excerpt :
Therefore, patients with CIDs have longer survival but experience more CV-related disease.29 The burden of CVD in CID is well understood, but mostly studied in RA and SLE,32,33 for which studies in RA and SLE report 1.5- to 5-fold increased risk for incident CVD compared with a non-CID population.14,34 Using a population-based cohort with expansive medical record review, our study shows an increased incidence of CVD occurrence among patients with SSc.
To characterize cardiovascular (CV) risk factors and outcomes among incident cases of systemic sclerosis (SSc) in a population-based cohort.
Medical records of patients with SSc diagnosed in Olmsted County, Minnesota, between January 1, 1980, and December 31, 2016, were reviewed to identify 78 incident SSc cases. The comparators were 156 sex- and age-matched individuals from the same population. Data for SSc characteristics, traditional CV risk factors, and CV events were collected. Cumulative incidence was adjusted for the competing risk for death.
During a median follow-up of 9.8 (SSc) and 9.2 years (non-SSc), 21 patients with SSc and 17 patients without SSc developed CV events, corresponding to 10-year cumulative incidence of 24.4% and 15.2%, respectively. The risk for incident CV disease was increased by 2-fold (hazard ratio, 2.38; 95% CI, 1.28-4.43) in patients with SSc vs comparators, predominately due to coronary artery disease (hazard ratio, 2.35; 95% CI, 1.17-4.71). Mean body mass index and prevalence of diabetes mellitus were lower in SSc vs non-SSc. There was no significant difference in smoking, hypertension, or hyperlipidemia. Observed CV events were increased compared with CV events predicted by the Framingham Risk Score and American College of Cardiology/American Heart Association score with standardized incident ratios of 4.16 (95% CI, 2.16-7.99) and 5.69 (95% CI, 2.71-11.94), respectively.
Patients with SSc are at >2-fold increased risk for experiencing a CV event compared with persons without SSc. Framingham Risk Score and American College of Cardiology/American Heart Association score dramatically underestimate CV risk in SSc.
Cardiovascular risk in myositis patients compared with the general population
2024, Rheumatology (United Kingdom)
Low utilization of statins in patients with dermatomyositis/polymyositis and hyperlipidemia: a multicenter USA-based study (2013–2023)
2024, Clinical Rheumatology
YKL-40 serum levels are predicted by inflammatory state, age and diagnosis of idiopathic inflammatory myopathies
2023, Scientific Reports
First study demonstrating speckle tracking echocardiography has prognostic value in patients with idiopathic inflammatory myopathies
2023, International Journal of Cardiovascular Imaging

View all citing articles on Scopus

: Authors׳ contributions: All authors had access to the data and a role in writing the manuscript.

View full text

Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis of observational studies

Abstract

Objectives

Methods

Result

Conclusion

Introduction

Section snippets

Search strategy

Result

Discussion

Conclusion

Int J Cardiol

Polymyositis and dermatomyositis-I

New Engl J Med

Polymyositis and dermatomyositis (second of tow parts)

New Engl J Med

Atherosclerosis in patients with autoimmune disorders

Arterioscler Thromb Vasc Biol

Inflammation in atherosclerosis

Nature

Cardiovascular death in rheumatoid arthritis: a population-based study

Arthritis Rheum

Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus

Rheumatology (Oxford)

Psoriasis and cardiovascular diseases

Acta Cardiol

Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Eur J Epidemiol

Measuring inconsistency in metaanalyses

Br Med J

Arterial events in persons with dermatomyositis and polymyositis

J Rheumatol

Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden

PLoS One

Dermatomyositis is associated with an increased risk of cardiovascular and cerebrovascular events: a Taiwanese population-based longitudinal follow up study

Br J Dermatol